Efficacy of the Triazole SCH 56592 against Leishmania amazonensis and Leishmania donovani in Experimental Murine Cutaneous and Visceral Leishmaniases
- 1 December 1999
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 43 (12) , 2910-2914
Abstract
Current therapy for leishmaniasis is unsatisfactory. Efficacious and safe oral therapy would be ideal. We examined the efficacy of SCH 56592, an investigational triazole antifungal agent, against cutaneous infection with Leishmania amazonensis and visceral infection with Leishmania donovani in BALB/c mice. Mice were infected in the ear pinna and tail with L. amazonensis promastigotes and were treated with oral SCH 56592 or intraperitoneal amphotericin B for 21 days. At doses of 60 and 30 mg/kg/day, SCH 56592 was highly efficacious in treating cutaneous disease, and at a dose of 60 mg/kg/day, it was superior to amphotericin B at a dose of 1 mg/kg/day. The means of tail lesion sizes were 0.32 ± 0.12, 0.11 ± 0.06, 0.17 ± 0.07, and 0.19 ± 0.08 mm for controls, SCH 56592 at 60 and 30 mg/kg/day, and amphotericin B recipients, respectively ( P = 0.0003, 0.005, and 0.01, respectively). Parasite burden in draining lymph nodes confirmed these efficacy findings. In visceral leishmaniasis due to L. donovani infection, mice treated with SCH 56592 showed a 0.5- to 1-log-unit reduction in parasite burdens in the liver and the spleen compared to untreated mice. Amphotericin B at 1 mg/kg/day was superior to SCH 56592 in the treatment of visceral infection, with a 2-log-unit reduction in parasite burdens in both the liver and spleen. These studies indicate very good activity of SCH 56592 against cutaneous leishmaniasis due to L. amazonensis infection and, to a lesser degree, against visceral leishmaniasis due to L. donovani infection in susceptible BALB/c mice.Keywords
This publication has 15 references indexed in Scilit:
- Efficacies of KY62 against Leishmania amazonensis and Leishmania donovani in Experimental Murine Cutaneous Leishmaniasis and Visceral LeishmaniasisAntimicrobial Agents and Chemotherapy, 1998
- In vitro activity of SCH-56592 and comparison with activities of amphotericin B and itraconazole against Aspergillus sppAntimicrobial Agents and Chemotherapy, 1997
- Itraconazole and leishmaniasis: A randomised double-blind trial in cutaneous diseaseInternational Journal for Parasitology, 1996
- Treatment of Cutaneous Leishmaniasis With ItraconazoleArchives of Dermatology, 1996
- Visceral leishmaniasis and HIV-1 co-infection in southern FranceTransactions of the Royal Society of Tropical Medicine and Hygiene, 1995
- Amphotericin versus sodium stibogluconate in first-line treatment of Indian kala-azarThe Lancet, 1994
- Pancreatitis Induced by Pentavalent Antimonial Agents During Treatment of LeishmaniasisClinical Infectious Diseases, 1994
- Successful Treatment of Visceral Leishmaniasis with Allopurinol plus Ketoconazole in a Renal Transplant Recipient after the Occurrence of Pancreatitis Due to StibogluconateClinical Infectious Diseases, 1993
- Therapy and Prophylaxis of Systemic Protozoan InfectionsDrugs, 1990
- Effects of ketoconazole on sterol biosynthesis by Leishmania mexicana mexicana amastigotes in murine macrophage tumor cellsMolecular and Biochemical Parasitology, 1986